Selective visuoconstructional impairment following mild COVID-19 with inflammatory and neuroimaging correlation findings

Imagem de Miniatura
Arquivos
art_PAULA_Selective_visuoconstructional_impairment_following_mild_COVID19_with_inflammatory_2023.PDF (2.01 MB)
Citações na Scopus
13
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGERNATURE
Autores
PAULA, Jonas Jardim de
PAIVA, Rachel E. R. P.
SOUZA-SILVA, Nathalia Gualberto
ROSA, Daniela Valadao
COIMBRA, Roney Santos
COSTA, Danielle de Souza
DUTENHEFNER, Pedro Robles
OLIVEIRA, Henrique Soares Dutra
CAMARGOS, Sarah Teixeira
Citação
MOLECULAR PSYCHIATRY, v.28, n.2, p.553-563, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
People recovered from COVID-19 may still present complications including respiratory and neurological sequelae. In other viral infections, cognitive impairment occurs due to brain damage or dysfunction caused by vascular lesions and inflammatory processes. Persistent cognitive impairment compromises daily activities and psychosocial adaptation. Some level of neurological and psychiatric consequences were expected and described in severe cases of COVID-19. However, it is debatable whether neuropsychiatric complications are related to COVID-19 or to unfoldings from a severe infection. Nevertheless, the majority of cases recorded worldwide were mild to moderate self-limited illness in non-hospitalized people. Thus, it is important to understand what are the implications of mild COVID-19, which is the largest and understudied pool of COVID-19 cases. We aimed to investigate adults at least four months after recovering from mild COVID-19, which were assessed by neuropsychological, ocular and neurological tests, immune markers assay, and by structural MRI and (18)FDG-PET neuroimaging to shed light on putative brain changes and clinical correlations. In approximately one-quarter of mild-COVID-19 individuals, we detected a specific visuoconstructive deficit, which was associated with changes in molecular and structural brain imaging, and correlated with upregulation of peripheral immune markers. Our findings provide evidence of neuroinflammatory burden causing cognitive deficit, in an already large and growing fraction of the world population. While living with a multitude of mild COVID-19 cases, action is required for a more comprehensive assessment and follow-up of the cognitive impairment, allowing to better understand symptom persistence and the necessity of rehabilitation of the affected individuals.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/53065
Referências
  1. Aarsland D, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00280-3
  2. Alemanno F, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246590
  3. American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI [10.1176/appi.books.9780890425596, DOI 10.1176/APPI.BOOKS.9780890425596]
  4. Amin M, 2021, EUR J GASTROEN HEPAT, V33, P309, DOI 10.1097/MEG.0000000000001808
  5. Ashton VL, 2005, J CLIN EXP NEUROPSYC, V27, P55, DOI 10.1080/138033990513636
  6. Azevedo RB, 2021, J HUM HYPERTENS, V35, P4, DOI 10.1038/s41371-020-0387-4
  7. Bai SW, 2021, FRONT AGING NEUROSCI, V13, DOI 10.3389/fnagi.2021.717002
  8. Banuelos C, 2014, J NEUROSCI, V34, P3457, DOI 10.1523/JNEUROSCI.5192-13.2014
  9. Biesbroek JM, 2014, NEUROPSYCHOLOGIA, V62, P68, DOI 10.1016/j.neuropsychologia.2014.07.013
  10. Blomberg B, 2021, NAT MED, V27, P1607, DOI 10.1038/s41591-021-01433-3
  11. Bowie CR, 2006, NAT PROTOC, V1, P2277, DOI 10.1038/nprot.2006.390
  12. Villeda SA, 2011, NATURE, V477, P90, DOI 10.1038/nature10357
  13. Villoslada P, 2004, PROG BRAIN RES, V146, P403
  14. Zhou HT, 2020, J PSYCHIATR RES, V129, P98, DOI 10.1016/j.jpsychires.2020.06.022
  15. Brian DA, 2005, CURR TOP MICROBIOL, V287, P1, DOI 10.1007/3-540-26765-4_1
  16. Chen RR, 2021, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.573095
  17. Cheriyan J, 2012, ARCH NEUROL-CHICAGO, V69, P82, DOI 10.1001/archneurol.2011.674
  18. Cipollini V, 2019, FRONT NEUROANAT, V13, DOI 10.3389/fnana.2019.00095
  19. Codarri L, 2011, NAT IMMUNOL, V12, P560, DOI 10.1038/ni.2027
  20. Cowley TJ, 2010, J NEUROVIROL, V16, P427, DOI 10.3109/13550284.2010.529238
  21. Crowley T, 2016, BRAIN BEHAV IMMUN, V54, P260, DOI 10.1016/j.bbi.2016.02.001
  22. D'Antonio F, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0445
  23. Dai XJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067666
  24. Davies SR, 2011, J CLIN EXP NEUROPSYC, V33, P820, DOI 10.1080/13803395.2011.574608
  25. Davis HE, 2021, ECLINICALMEDICINE, V38, DOI 10.1016/j.eclinm.2021.101019
  26. Carvalho PMD, 2020, PSYCHIAT RES, V286, DOI 10.1016/j.psychres.2020.112902
  27. de Paula JJ., 2021, MEDRXIV, DOI [10.1101/2021.02.18.21251442, DOI 10.1101/2021.02.18.21251442]
  28. Paula Jonas Jardim de, 2015, Dement. neuropsychol., V9, P258, DOI [10.1590/1980-57642015DN93000008, 10.1590/1980-57642015dn93000008]
  29. Desole C, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.683609
  30. Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095
  31. DiSabato DJ, 2016, J NEUROCHEM, V139, P136, DOI 10.1111/jnc.13607
  32. Douaud G, 2022, NATURE, V604, P697, DOI [10.1038/s41586-022-04569-5, 10.1101/2021.06.11.21258690]
  33. Economo CV., 1932, DTSCH F R NERVENHEIL, V124, P84, DOI [10.1007/BF01652904, DOI 10.1007/BF01652904]
  34. Elliott P, 2022, SCIENCE, V375, P1406, DOI 10.1126/science.abn8347
  35. Ellul MA, 2020, LANCET NEUROL, V19, P767, DOI 10.1016/S1474-4422(20)30221-0
  36. Fernandez-Castaneda Anthony, 2022, bioRxiv, DOI [10.1007/s43683-022-00090-3, 10.1101/2022.01.07.475453]
  37. Gainotti Guido, 2018, Handb Clin Neurol, V151, P331, DOI 10.1016/B978-0-444-63622-5.00016-4
  38. Galvin JE, 2005, NEUROLOGY, V65, P559, DOI 10.1212/01.wnl.0000172958.95282.2a
  39. Gibson EM, 2021, TRENDS NEUROSCI, V44, P441, DOI 10.1016/j.tins.2021.02.003
  40. GIROUD M, 1995, J NEUROL NEUROSUR PS, V59, P238, DOI 10.1136/jnnp.59.3.238
  41. Gomes C, 2020, BRAZILIAN J IMPLANTO, P2
  42. Gong RJ, 2004, J AM SOC NEPHROL, V15, P2868, DOI 10.1097/01.ASN.0000141962.44300.3A
  43. Hampshire A, 2021, ECLINICALMEDICINE, V39, DOI 10.1016/j.eclinm.2021.101044
  44. Han KM, 2021, J CLIN NEUROL, V17, P503, DOI 10.3988/jcn.2021.17.4.503
  45. Hartlage-Rubsamen M, 2015, ACTA NEUROPATHOL, V129, P565, DOI 10.1007/s00401-015-1395-2
  46. Honigsbaum M, 2013, LANCET, V381, P988, DOI 10.1016/S0140-6736(13)60701-1
  47. Hosp JA, 2021, BRAIN, V144, P1263, DOI 10.1093/brain/awab009
  48. Hosseini S, 2018, J NEUROSCI, V38, P3060, DOI 10.1523/JNEUROSCI.1740-17.2018
  49. iapp, BRAZ GEN DAT PROT LA
  50. Ip WK, 2007, IMMUNOLOGY, V122, P532, DOI 10.1111/j.1365-2567.2007.02668.x
  51. Kalil RS, 2021, J NEUROVIROL, V27, P810, DOI 10.1007/s13365-021-00944-6
  52. Kessels RPC, 2008, ASSESSMENT, V15, P426, DOI 10.1177/1073191108315611
  53. Kiatkittikul P, 2022, NUCL MED MOLEC IMAG, V56, P29, DOI 10.1007/s13139-021-00730-6
  54. Kim KH, 2017, J HOSP INFECT, V95, P207, DOI 10.1016/j.jhin.2016.10.008
  55. Kravitz DJ, 2011, NAT REV NEUROSCI, V12, P217, DOI 10.1038/nrn3008
  56. Lauw FN, 2000, J IMMUNOL, V165, P2783, DOI 10.4049/jimmunol.165.5.2783
  57. Lepoutre V, 2009, FRONT BIOSCI-LANDMRK, V14, P1152, DOI 10.2741/3300
  58. Liu PY, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22179112
  59. Lodder J, 2015, AUTOPHAGY, V11, P1280, DOI 10.1080/15548627.2015.1058473
  60. Logue JK, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.0830
  61. Lu YP, 2020, ECLINICALMEDICINE, V25, DOI 10.1016/j.eclinm.2020.100484
  62. Mandal PK, 2012, J ALZHEIMERS DIS, V31, pS117, DOI 10.3233/JAD-2012-120901
  63. Manjunatha N, 2020, INDIAN J PSYCHIAT, V62, P320, DOI 10.4103/psychiatry.IndianJPsychiatry_236_20
  64. MARI JD, 1986, BRIT J PSYCHIAT, V148, P23, DOI 10.1192/bjp.148.1.23
  65. Martin C, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0260843
  66. Mattioli F, 2021, J NEUROL, V268, P4422, DOI 10.1007/s00415-021-10579-6
  67. Menninger KA, 1926, AM J PSYCHIAT, V5, P469
  68. Monzon ME, 2011, AM J PHYSIOL-LUNG C, V300, pL204, DOI 10.1152/ajplung.00292.2010
  69. Morbelli S, 2022, EUR J NUCL MED MOL I, V49, P1939, DOI 10.1007/s00259-021-05666-9
  70. Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7
  71. Najt Pablo, 2021, Brain Behav Immun Health, V16, P100290, DOI 10.1016/j.bbih.2021.100290
  72. Nitrini Ricardo, 2008, Dement. neuropsychol., V2, P310, DOI 10.1590/S1980-57642009DN20400014
  73. Norden DM, 2013, NEUROPATH APPL NEURO, V39, P19, DOI 10.1111/j.1365-2990.2012.01306.x
  74. Norden DM, 2016, GLIA, V64, P300, DOI 10.1002/glia.22930
  75. Oschwald J, 2020, REV NEUROSCIENCE, V31, P1, DOI 10.1515/revneuro-2018-0096
  76. Pan WH, 2008, AM J PHYSIOL-CELL PH, V294, pC1436, DOI 10.1152/ajpcell.00489.2007
  77. Petersen RC, 2009, ARCH NEUROL-CHICAGO, V66, P1447, DOI 10.1001/archneurol.2009.266
  78. Premraj L, 2022, J NEUROL SCI, V434, DOI 10.1016/j.jns.2022.120162
  79. Puntmann VO, 2020, JAMA CARDIOL, V5, P1265, DOI 10.1001/jamacardio.2020.3557
  80. Raison CL, 2006, TRENDS IMMUNOL, V27, P24, DOI 10.1016/j.it.2005.11.006
  81. Riester K, 2020, BRAIN BEHAV IMMUN, V87, P243, DOI 10.1016/j.bbi.2019.12.007
  82. Salanova V, 2012, J CLIN NEUROPHYSIOL, V29, P392, DOI 10.1097/WNP.0b013e31826c9ebc
  83. Semnic MD, 2021, VOJNOSANIT PREGL, V78, P40, DOI 10.2298/VSP191220039S
  84. Seydell-Greenwald A, 2017, NEUROPSYCHOLOGIA, V106, P194, DOI 10.1016/j.neuropsychologia.2017.10.005
  85. Shin MS, 2006, NAT PROTOC, V1, P892, DOI 10.1038/nprot.2006.115
  86. Singhal E, 2011, J BIOL CHEM, V286, P32054, DOI 10.1074/jbc.M111.271247
  87. Sollini M, 2022, EUR J NUCL MED MOL I, V49, P791, DOI 10.1007/s00259-021-05652-1
  88. Son KB, 2021, B WORLD HEALTH ORGAN, V99, P62, DOI 10.2471/BLT.20.257758
  89. Staples KJ, 2007, J IMMUNOL, V178, P4779, DOI 10.4049/jimmunol.178.8.4779
  90. Strauss E, 2006, COMPENDIUM NEUROPSYC, V3rd
  91. Sudre CH, 2021, NAT MED, V27, DOI 10.1038/s41591-021-01292-y
  92. Tamassia N, 2010, FASEB J, V24, P1365, DOI 10.1096/fj.09-145573
  93. Tansey MG, 2007, EXP NEUROL, V208, P1, DOI 10.1016/j.expneurol.2007.07.004
  94. Tenza-Ferrer H, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00306
  95. Thomson CA, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-73
  96. Tomida M, 2004, ONCOGENE, V23, P679, DOI 10.1038/sj.onc.1207190
  97. Tsai LK, 2004, ARCH NEUROL-CHICAGO, V61, P1669, DOI 10.1001/archneur.61.11.1669
  98. Vanderlind WM, 2021, CURR OPIN PSYCHIATR, V34, P420, DOI 10.1097/YCO.0000000000000713
  99. Vazirinejad R, 2014, NEUROIMMUNOMODULAT, V21, P322, DOI 10.1159/000357780
  100. Vecile E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053265
  101. Versace V, 2021, CLIN NEUROPHYSIOL, V132, P1138, DOI 10.1016/j.clinph.2021.03.001

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - LIM/21
Artigos e Materiais de Revistas Científicas - LIM/45
Artigos e Materiais de Revistas Científicas - ODS/03